Focus: IO Biotech is a Copenhagen-based immuno-oncology biotech founded in 2012, focused on therapeutic cancer vaccines and checkpoint inhibitor combinations. As a public company (IOBT), it operates at clinical-stage with multiple Phase 2 programs across solid and hematologic malignancies.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow IO Biotech to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from IO Biotech's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for IO Biotech
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Big tech- and pharma-backed Iambic Therapeutics aims for $135m IPO - Pharmaceutical Technology
Big tech- and pharma-backed Iambic Therapeutics aims for $135m IPO Pharmaceutical Technology
Jennifer Taubert announces retirement from J&J; Takeda’s global TYK2 leader exits - Endpoints News
Jennifer Taubert announces retirement from J&J; Takeda’s global TYK2 leader exits Endpoints News
8-K Filing: Neuphoria Therapeutics Inc. (NEUP) (CIK 0001191070) — INVESTOR PRESENTATION OF SCANCELL HOLDINGS PLC, DATED JULY 2026
INVESTOR PRESENTATION OF SCANCELL HOLDINGS PLC, DATED JULY 2026
Cue lines up new CMO and research head—Chutes & Ladders - Fierce Biotech
Cue lines up new CMO and research head—Chutes & Ladders Fierce Biotech
Zealand Pharma gets its US marketing leader from Lilly; Bexorg turns to Biohaven for CSO hire - Endpoints News
Zealand Pharma gets its US marketing leader from Lilly; Bexorg turns to Biohaven for CSO hire Endpoints News
Elevara Medicines appoints biotech veteran as CEO - The Pharma Letter
Elevara Medicines appoints biotech veteran as CEO The Pharma Letter
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Bankruptcy within past 12 months combined with zero hiring signals acute organizational distress; significant restructuring risk and potential further layoffs.
Recent peer-reviewed publications with author affiliations at this company
IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma.
Five-year clinical outcome and immune biomarkers of durable response from the MM1636 trial on IDO/PD-L1 vaccination and PD-1 blockade in first line metastatic melanoma.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo